Molecular differentiation of OX40- and OX40L-targeted biologics using AlphaFold3 and molecular dynamics simulations
Journal of Investigative Dermatology · 2026
DOI: 10.1016/j.jid.2026.01.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2026. Verfasst von Kelsey Nolden und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Receptors, OX40, OX40 Ligand, Dermatitis, Atopic, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, National Institute of General Medical Sciences, Medical College of Wisconsin.
Abstract (Originalsprache)
Atopic dermatitis is a chronic inflammatory skin disorder that affects over 200 million people worldwide. Although disease etiology is multifaceted, the immune checkpoint molecules OX40 and OX40L have a critical role in disease development. Recent clinical trials demonstrated that the OX40-targeting antibodies rocatinlimab (KHK4083/AMG-451) and telazorlimab (GBR-830/ISB-830) and the OX40L-targeting antibody amlitelimab (KY1005) significantly improve symptoms of atopic dermatitis. However, the epitopes where these antibodies bind OX40 and OX40L remain unclear, and therefore, so do the mechanisms through which they specifically disrupt OX40-OX40L signaling. To address this, computational modeling was performed to predict antibody-protein cocomplexes, and their interaction interfaces were characterized. Binding-free energy of specific OX40 or OX40L residue-residue interactions within 5 Å of the antibody binding interface was analyzed using Molecular Mechanics Poisson-Boltzmann Surface Area with a per-residue energy decomposition analysis. Our analysis suggests that rocatinlimab and amlitelimab directly inhibit OX40-OX40L interactions by physically blocking the cognate OX40-OX40L interface through steric occlusion, whereas telazorlimab disrupts a critical OX40-OX40L bond. Together, this work provides molecular characterization of the epitopes of OX40- and OX40L-targeted biologics emerging in dermatology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Department of Chemistry, Yale University, New Haven, Connecticut, USA.
- Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA; Program in Translational Biomedicine, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address: christopher.bunick@yale.ed…
Förderung
- NIAMS NIH HHS
- National Institute of General Medical Sciences
- Medical College of Wisconsin
- National Institutes of Health
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Nolden, K., Shi, Y., Batista, V. S., & Bunick, C. G. (2026). Molecular differentiation of OX40- and OX40L-targeted biologics using AlphaFold3 and molecular dynamics simulations. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2026.01.024
Vancouver
Nolden K, Shi Y, Batista VS, Bunick CG. Molecular differentiation of OX40- and OX40L-targeted biologics using AlphaFold3 and molecular dynamics simulations. Journal of Investigative Dermatology. 2026. doi:10.1016/j.jid.2026.01.024
BibTeX
@article{Nolden2026,
author = {Nolden, Kelsey and Shi, Yuanjun and Batista, Victor S and Bunick, Christopher G},
title = {Molecular differentiation of OX40- and OX40L-targeted biologics using AlphaFold3 and molecular dynamics simulations},
journal = {Journal of Investigative Dermatology},
year = {2026},
doi = {10.1016/j.jid.2026.01.024}
}
EUVIMED